Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5389-5398

  Hsu, Chung Ping ^a,b   Lee, Li Wen ^a   Tang, Sheau Chung ^c,d   Hsin, I Lun ^c,d   Lin, Yu Wen ^c,d   Ko, Jiunn Liang ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Ets 2; hTERT gene promoter; Lung cancer; Myc; Transcription factor

Indexed keywords

EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; PROTEIN KINASE B INHIBITOR; SMALL INTERFERING RNA; TELOMERASE; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TERT PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS 2;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ETS 2 GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HTERT GENE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MAD GENE; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 84938215807     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3204-x     Document Type: Article

References (25)

1. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res. 2000;87:540–2.
2. Dwyer J, Li H, Xu D, Liu JP. Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann N Y Acad Sci. 2007;1114:36–47.
3. Hsu CP, Miaw J, Hsia JY, Shai SE, Chen CY. Concordant expression of the telomerase-associated genes in non-small cell lung cancer. Eur J Surg Oncol. 2003;29:594–9.
4. Wu TC, Lin P, Hsu CP, Huang YJ, Chen CY, Chung WC, et al. Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer. 2003;41:163–9.
5. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99:1528–38.
6. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137–42.
7. Hsu CP, Miaw J, Shai SE, Chen CY. Correlation between telomerase expression and terminal restriction fragment length ratio in non-small cell lung cancer—an adjusted measurement and its clinical significance. Eur J Cardiothorac Surg. 2004;26:425–31.
8. Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature. 1990;346:191–3.
9. Borie R, Kannengiesser C, Crestani B. Familial forms of nonspecific interstitial pneumonia/idiopathic pulmonary fibrosis: clinical course and genetic background. Curr Opin Pulm Med. 2012;18:455–61.
10. Hsu CP, Hsu NY, Lee LW, Ko JL. Ets-2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer. 2006;42:1466–74.
11. Park NH, Guo W, Kim HR, Kang MK. C-myc and sp1/3 are required for transactivation of hamster telomerase catalytic subunit gene promoter. Int J Oncol. 2001;19:755–61.
12. Kim SJ, Lee HS, Shin JH, Kim CG, Jeong S, Park K, et al. Preferentially enhanced gene expression from a synthetic human telomerase reverse transcriptase promoter in human cancer cells. Oncol Rep. 2006;16:975–9.
13. McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol. 2003;77:9852–61.
14. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res. 1998;4:1603–8.
15. Liao CH, Hsiao YM, Hsu CP, Lin MY, Wang JC, Huang YL, et al. Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from ganoderma tsugae in A549 human lung adenocarcinoma cell line. Mol Carcinog. 2006;45:220–9.
16. Maida Y, Kyo S, Kanaya T, Wang Z, Yatabe N, Tanaka M, et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene. 2002;21:4071–9.
17. Xiao X, Athanasiou M, Sidorov IA, Horikawa I, Cremona G, Blair D, et al. Role of Ets/Id proteins for telomerase regulation in human cancer cells. Exp Mol Pathol. 2003;75:238–47.
18. Dwyer JM, Liu JP. Ets-2 transcription factor, telomerase activity and breast cancer. Clin Exp Pharmacol Physiol. 2010;37:83–7.
19. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, et al. Ets-2 and p160 proteins collaborate to regulate c-myc in endocrine resistant breast cancer. Oncogene. 2008;27:3021–31.
20. Xu D, Dwyer J, Li H, Duan W, Liu JP. Ets-2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem. 2008;283:23567–80.
21. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A. 2001;98:3826–31.
22. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol. 2000;20:556–62.
23. Li CT, Hsiao YM, Wu TC, Lin YW, Yeh KT, Ko JL. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. J Cell Biochem. 2011;112:3044–53.
24. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of egfr is inhibited by gefitinib (“Iressa”, ZD1839). Oncol Rep. 2004;12:1053–7.
25. Deng WG, Jayachandran G, Wu G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem. 2007;282:26460–70.